Neuralstem CEO Blog

RSS
  • “Common sense is not so common.”

    - Voltaire

Posted: October 28th, 2014

The Washington Post ran an article recently focused on the fact that ALS patients may soon lose Medicare coverage for devices which help them to communicate as their ability to speak wanes through the terrible attrition of the disease.

For roughly the past 15 years, Medicare has covered about 80% of the basic cost of speech generating machines like those that many ALS patients use. We have all become familiar with them if not through personal contact, then by seeing various public figures such as Steven Hawking and Steve Gleason use them. They are a godsend for patients and their families. Today, there are many programs where patients can record a full vocabulary when they are first diagnosed and the machines will later actually speak with the patient’s own voice and inflections.

Read more...

  • “Courage is grace under pressure”

    - Ernest Hemingway

Posted: August 25th, 2014

The ALS “Ice Bucket Challenge” is a wonderful viral campaign, which has swept the country and now the world, to raise money and awareness for ALS research. Though there were versions of the challenge previously circulating, the idea for the ALS Ice Bucket Challenge is attributed largely to Pete Frates, a young ALS patient who I have the honor to have met. You can (and should) go to Pete’s site and learn more about his amazing journey. Like all ALS patients, Pete’s story is not likely one with a happy ending, and he knows that. The odds are very strongly stacked against him, but he continues to fight, he continues to inspire and he continues to lead. Pete’s life is truly the definition of grace under pressure, and we are all the beneficiaries of his love and his courage. As of Sunday August 24th, something close to $70 million has already been raised for ALS research as a result of this awareness campaign, and I have no doubt that the awareness raised will lead to a sustained increase in much needed funding from all sources.

Read more...

  • “I love it when a plan comes together.”

    - Colonel John “Hannibal” Smith, The A Team

Posted: August 13th, 2014

There are times in life when everything seems to go wrong; then there are those (rare, for most of us) times, when things fall into place. There is no way to understand the “why” of these times, nor the when, but we can feel it when it happens.

Read more...

  • “There is nothing either good or bad, but thinking makes it so.”

    - William Shakespeare, Hamlet

Posted: July 30th, 2014

Shakespeare may have been thinking more of the innate nature of things when he penned this particular sentiment; but in the world of clinical trials, “attitude,” or merely what a patients thinks about a treatment can have a serious impact on how that treatment works, or doesn’t.

Read more...

  • “…FDA has demonstrated its commitment to supporting access to experimental therapies for patients living with serious diseases. The agency is an important part of the process, helping to ensure that patients are protected from potentially harmful drugs or one that doesn't work. Allowing access to investigational therapies requires the cooperation of others, including drug companies and doctors, not just FDA. In cases where a company has initially denied access, FDA has stepped in to help. FDA is proud of its record facilitating access to safe, effective therapies for patients who need them as quickly as possible.”

    - Margaret Hamburg: Commissioner, U.S. FDA

Posted: June 6th, 2014

This is from the first written comment that Dr. Hamburg has made with respect to the Right to Try (RTT) bill, recently signed into law in Colorado, now making its way across the country. To those of you who follow this area, it may surprise you to know that Neuralstem agrees with Commissioner Hamburg; the FDA is an indispensable party in this process. Indeed the RTT bill relies heavily on their expertise and diligence. That is why the bill only applies to fatal diseases, and only to drugs or therapies that have passed an FDA-approved safety trial, and are still actively being developed under the FDA umbrella in further trials. Any drug that dropped out of this legislative “inclusion” criteria would no longer be eligible for delivery under the legislation. At Neuralstem we are involved in developing our cell therapies all over the world, and I can attest to the fact that the FDA’s science and processes are considered the gold standard. Again, this is exactly why this important safeguard is incorporated into the RTT bill.

Read more...

Privacy and Terms ©Neuralstem, Inc. 2014